Article
Epigenetic inhibitors eliminate senescent melanoma BRAFV600E cells that survive long‑term BRAF inhibition.
International journal of oncology - 1 Jun 2020
Madorsky Rowdo Florencia Paula, Barón Antonela, Gallagher Stuart John, Hersey Peter, Emran Abdullah Al, Von Euw Erika M, Barrio María Marcela, Mordoh José
Abstract excerpt
It is estimated that ~50% of patients with melanoma harbour B‑Raf (BRAF)V600 driver mutations, with the most common of these being BRAFV600E, which leads to the activation of mitogen‑activated protein kinase proliferative and survival pathways. BRAF inhibitors are used extensively to treat BRAF‑mutated metastatic melanoma; however, acquired resistance occurs in the majority of patients. The effects of long‑term...
Topics
- Antineoplastic Combined Chemotherapy Protocols
- Cell Line, Tumor
- Cellular Senescence
- Drug Resistance, Neoplasm
- Epigenesis, Genetic
- Female
- Gene Expression Profiling
- Gene Expression Regulation, Neoplastic
- Gene Regulatory Networks